专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明授权

US5426177A Ciliary neurotrophic factor receptor 失效
标题翻译：睫状神经营养因子受体
公开(公告)号：US5426177A
公开(公告)日：1995-06-20
申请号：US676647
申请日：1991-03-28
申请人： Samuel Davis , Stephen P. Squinto , Mark E. Furth , George D. Yancopoulos
发明人： Samuel Davis , Stephen P. Squinto , Mark E. Furth , George D. Yancopoulos
IPC分类号： A61K38/00 , C07K14/705 , C12Q1/68
CPC分类号： C12Q1/6883 , C07K14/705 , A61K38/00 , C07K2319/00 , C12Q2600/158 , Y10S530/839
摘要： The present invention relates to the ciliary neurotrophic factor (CNTF) receptor, and provides for CNTF receptor nucleic acid and amino acid sequences. It also relates to (i) assay systems for detecting CNTF activity; (ii) experimental model systems for studying the physiologic role of CNTF; (ii) diagnostic techniques for identifying CNTF-related neurologic conditions; (iv) therapeutic techniques for the treatment of CNTF-related neurologic and muscular conditions, and (v) methods for identifying molecules homologous to CNTF and CNTFR.
摘要翻译：本发明涉及睫状神经营养因子（CNTF）受体，并提供CNTF受体核酸和氨基酸序列。它还涉及（i）用于检测CNTF活性的测定系统; （ii）研究CNTF生理作用的实验模型系统; （ii）用于鉴定CNTF相关神经病症的诊断技术; （iv）用于治疗CNTF相关神经和肌肉病症的治疗技术，以及（v）用于鉴定与CNTF和CNTFR同源的分子的方法。

32. 发明授权

US5266490A Mammalian expression vector 失效
标题翻译：哺乳动物表达载体
公开(公告)号：US5266490A
公开(公告)日：1993-11-30
申请号：US678408
申请日：1991-03-28
申请人： Samuel Davis , George D. Yancopoulos
发明人： Samuel Davis , George D. Yancopoulos
IPC分类号： C07K14/48 , C07K14/71 , C07K14/82 , C12N15/85 , C12N15/79 , C12N15/12 , C12N15/18
CPC分类号： C12N15/85 , C07K14/48 , C07K14/71 , C07K14/82 , C07K2319/00 , C07K2319/41 , C07K2319/61 , C07K2319/75 , C12N2800/108
摘要： DNA plasmid expression vector, pCMX, enables cDNA expression cloning in mammalian cell culture. This novel expression vector exhibits a marked increase in gene expression when compared to its parental plasmid construction.
摘要翻译： DNA质粒表达载体pCMX能够在哺乳动物细胞培养物中进行cDNA表达克隆。当与其亲本质粒构建相比时，该新型表达载体表现出基因表达的显着增加。

33. 发明授权

US08084234B2 Isolated nucleic acid molecules encoding a fusion protein capable of binding VEGF 有权
标题翻译：分离编码能够结合VEGF的融合蛋白的核酸分子
公开(公告)号：US08084234B2
公开(公告)日：2011-12-27
申请号：US12715128
申请日：2010-03-01
申请人： Nicholas J. Papadopoulos , Samuel Davis , George D. Yancopoulos
发明人： Nicholas J. Papadopoulos , Samuel Davis , George D. Yancopoulos
IPC分类号： C12N15/62 , C12N15/63 , C07H21/00
CPC分类号： C07K14/71 , A61K38/00 , C07K16/22 , C07K19/00 , C07K2319/00 , C07K2319/30
摘要： Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.
摘要翻译：公开了具有改善的药代动力学的修饰的嵌合多肽。具体地，公开了已经以改善其药代动力学特征的方式修饰的修饰的嵌合Flt1受体多肽。还公开了制备和使用修饰的多肽的方法，包括但不限于使用修饰的多肽来降低或抑制哺乳动物的血浆渗透和/或血管通透性。

34. 发明申请

US20100221782A1 Modified Chimeric Polypeptides With Improved Pharmacokinetic Properties 有权
标题翻译：改进的嵌合多肽具有改善的药物动力学性质
公开(公告)号：US20100221782A1
公开(公告)日：2010-09-02
申请号：US12715128
申请日：2010-03-01
申请人： Nicholas J. Papadopoulos , Samuel Davis , George D. Yancopoulos
发明人： Nicholas J. Papadopoulos , Samuel Davis , George D. Yancopoulos
IPC分类号： C12P21/06 , C12N5/10 , C12N1/21 , C12N1/19 , C12N15/63 , C07H21/04
CPC分类号： C07K14/71 , A61K38/00 , C07K16/22 , C07K19/00 , C07K2319/00 , C07K2319/30
摘要： Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.
摘要翻译：公开了具有改善的药代动力学的修饰的嵌合多肽。具体地，公开了已经以改善其药代动力学特征的方式修饰的修饰的嵌合Flt1受体多肽。还公开了制备和使用修饰的多肽的方法，包括但不限于使用修饰的多肽来降低或抑制哺乳动物的血浆渗透和/或血管通透性。

35. 发明授权

US07374758B2 Modified chimeric polypeptides with improved pharmacokinetic properties and methods of using thereof 有权
标题翻译：具有改善的药代动力学性质的改良的嵌合多肽及其使用方法
公开(公告)号：US07374758B2
公开(公告)日：2008-05-20
申请号：US11016503
申请日：2004-12-17
申请人： Nicholas J. Papadopoulos , Samuel Davis , George D. Yancopoulos
发明人： Nicholas J. Papadopoulos , Samuel Davis , George D. Yancopoulos
IPC分类号： A61K38/18 , C07K14/71 , C12N15/62
CPC分类号： C07K14/71 , A61K38/00 , C07K16/22 , C07K19/00 , C07K2319/00 , C07K2319/30
摘要： Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.
摘要翻译：公开了具有改善的药代动力学的修饰的嵌合多肽。具体地，公开了已经以改善其药代动力学特征的方式修饰的修饰的嵌合Flt1受体多肽。还公开了制备和使用修饰的多肽的方法，包括但不限于使用修饰的多肽来降低或抑制哺乳动物的血浆渗透和/或血管通透性。

36. 发明授权

US07063965B2 Nucleic acid encoding TIE-2 ligand 失效
标题翻译：编码TIE-2配体的核酸
公开(公告)号：US07063965B2
公开(公告)日：2006-06-20
申请号：US10603293
申请日：2003-06-25
申请人： Samuel Davis , George D. Yancopoulos
发明人： Samuel Davis , George D. Yancopoulos
IPC分类号： C12N15/12 , C12N5/10 , C12N15/63
CPC分类号： A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/0306
摘要： The present invention provides for an isolated nucleic acid molecule encoding a human TIE-2 ligand. In addition, the invention provides for a receptorbody which specifically binds a human TIE-2 ligand. The invention also provides an antibody which specifically binds a human TIE-2 ligand. The invention further provides for an antagonist of human TIE-2. The invention further provides for a ligandbody which specifically binds TIE-2 receptor. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth, differentiation or migration of cells expressing the TIE-2 receptor, including, but not limited to, hematopoietic precursor cells, a method of blocking the growth, differentiation or migration of cells expressing the TIE-2 receptor including, but not limited to, hematopoietic precursor cells, and a method of attenuating or preventing tumor growth in a human.
摘要翻译：本发明提供了编码人TIE-2配体的分离的核酸分子。此外，本发明提供了特异性结合人TIE-2配体的受体体。本发明还提供了特异性结合人TIE-2配体的抗体。本发明进一步提供人TIE-2的拮抗剂。本发明进一步提供了特异性结合TIE-2受体的配体体。本发明还提供治疗组合物以及阻断血管生长的方法，促进新生血管形成的方法，促进表达TIE-2受体的细胞的生长，分化或迁移的方法，包括但不限于，造血前体细胞，阻断表达TIE-2受体的细胞的生长，分化或迁移的方法，包括但不限于造血前体细胞，以及减弱或预防人类肿瘤生长的方法。

37. 发明授权

US07045302B2 Expressed ligand-vascular intercellular signaling molecule 有权
标题翻译：表达配体 - 血管细胞间信号分子
公开(公告)号：US07045302B2
公开(公告)日：2006-05-16
申请号：US11073120
申请日：2005-03-04
申请人： Samuel Davis , George D. Yancopoulos
发明人： Samuel Davis , George D. Yancopoulos
IPC分类号： A61K39/00 , C07K16/00 , G01N33/35
CPC分类号： C12N15/8509 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2227/30 , A01K2267/01 , A01K2267/03 , A01K2267/0331 , A01K2267/0375 , A01K2267/0381 , A61K38/00 , C07K14/515 , C07K14/71 , C07K2319/00 , C07K2319/02
摘要： The present invention provides for a modified TIE-2 ligand 2 which has been altered by addition, deletion or substitution of one or more amino acids, or by way of tagging, with for example, the Fc portion of human IgG-1, but which retains its ability to bind the TIE-2 receptor.
摘要翻译：本发明提供了修饰的TIE-2配体2，其通过一个或多个氨基酸的添加，缺失或取代而被改变，或者通过例如使用例如人IgG-1的Fc部分进行标记而改变，但是哪些保留其结合TIE-2受体的能力。

38. 发明授权

US06441137B1 Expressed ligand-vascular intercellular signalling molecule 有权
标题翻译：表达配体 - 血管细胞间信号分子
公开(公告)号：US06441137B1
公开(公告)日：2002-08-27
申请号：US09709188
申请日：2000-11-09
申请人： Samuel Davis , George D. Yancopoulos
发明人： Samuel Davis , George D. Yancopoulos
IPC分类号： C12P2104
CPC分类号： C12N15/8509 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2227/30 , A01K2267/01 , A01K2267/03 , A01K2267/0331 , A01K2267/0375 , A01K2267/0381 , A61K38/00 , C07K14/515 , C07K14/71 , C07K2319/00 , C07K2319/02
摘要： The present invention provides for a modified TIE-2 ligand which has been altered by addition, deletion or substitution of one or more amino acids, or by way of tagging, with for example, the Fc portion of human IgG-1, but which retains its ability to bind the TIE-2 receptor. The invention further provides for a modified TIE-2 ligand which is a chimeric TIE-2 ligand comprising at least a portion of a first TIE-2 ligand and a portion of a second TIE-2 ligand which is different from the first. In a specific embodiment, the invention further provides for a chimeric TIE ligand comprising at least a portion of TIE-2 Ligand-1 and a portion of TIE-2 Ligand-2. In addition the present invention provides for isolated nucleic acid molecule encoding the modified TIE-2 ligands described. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE receptor, a method of blocking the growth or differentiation of a cell expressing the TIE receptor and a method of attenuating or preventing tumor growth in a human.
摘要翻译：本发明提供了修饰的TIE-2配体，其通过添加，缺失或取代一个或多个氨基酸，或通过标记，例如，人IgG-1的Fc部分，但保留其结合TIE-2受体的能力。本发明进一步提供了修饰的TIE-2配体，其是包含与第一TIE-2配体不同的至少一部分第一TIE-2配体和第二TIE-2配体的嵌合TIE-2配体。在一个具体实施方案中，本发明还提供了包含TIE-2配体-1的至少一部分和TIE-2配体-2的一部分的嵌合TIE配体。此外，本发明提供了编码所述修饰的TIE-2配体的分离的核酸分子。本发明还提供治疗组合物以及阻断血管生长的方法，促进新生血管形成的方法，促进表达TIE受体的细胞的生长或分化的方法，阻止生长或分化的方法表达TIE受体的细胞和减弱或预防人类肿瘤生长的方法。

39. 发明授权

US5892003A Ciliary neurotrophic factor receptor antibodies 失效
标题翻译：睫状神经营养因子受体抗体
公开(公告)号：US5892003A
公开(公告)日：1999-04-06
申请号：US585258
申请日：1996-01-11
申请人： Samuel Davis , Stephen P. Squinto , Mark E. Furth , George D. Yancopoulos
发明人： Samuel Davis , Stephen P. Squinto , Mark E. Furth , George D. Yancopoulos
IPC分类号： A61K38/00 , C07K14/705 , C12N15/09 , C12N15/11 , C12N15/31 , C12P19/34 , C12P21/02 , C12Q1/68 , C07K16/28
CPC分类号： C07K14/705 , A61K38/00 , C07K2319/00
摘要： The present invention relates to the ciliary neurotropic factor (CNTF) receptor, and provides for CNTF receptor antibodies. It also relates to diagnostic techniques for identifying CNTF-related neurologic conditions.
摘要翻译：本发明涉及睫状神经营养因子（CNTF）受体，并提供CNTF受体抗体。它还涉及用于鉴定CNTF相关神经病症的诊断技术。

40. 发明授权

US5648334A Methods of treatment using ciliary neurotrophic factor 失效
标题翻译：使用睫状神经营养因子的治疗方法
公开(公告)号：US5648334A
公开(公告)日：1997-07-15
申请号：US449329
申请日：1995-05-24
申请人： Samuel Davis , Stephen P. Squinto , Mark E. Furth , George D. Yancopoulos
发明人： Samuel Davis , Stephen P. Squinto , Mark E. Furth , George D. Yancopoulos
IPC分类号： A61K38/00 , C07K14/705 , C12N15/09 , C12N15/11 , C12N15/31 , C12P19/34 , C12P21/02 , C12Q1/68 , A61K38/17 , C07K14/475
CPC分类号： C07K14/705 , A61K38/00 , C07K2319/00
摘要： The present invention relates to a method of treatment of a neuromuscular or muscle disorder resulting from the loss of axonal contact with the muscle comprising administering an effective amount of ciliary neurotrophic factor. The invention also relates to a method of treatment of a disorder of a type of tissue or cell resulting from the loss of axonal contact with the cell comprising administering an effective amount of ciliary neurotrophic factor in which the type of tissue or cell expresses a CNTF receptor protein.
摘要翻译：本发明涉及治疗由于与肌肉轴突接触丧失而引起的神经肌肉或肌肉紊乱的方法，包括施用有效量的睫状神经营养因子。本发明还涉及一种治疗由于与细胞轴突接触丧失而导致的组织或细胞类型病症的方法，其包括施用有效量的睫状神经营养因子，其中组织或细胞的类型表达CNTF受体蛋白。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式